In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tekmira, Roche sign siRNA collaboration; terminated; now taken over by Arrowhead

Executive Summary

After signing an initial preliminary agreement one year ago, Canadian RNAi firm Tekmira Pharmaceuticals and Roche have finalized a deal to develop the Big Pharma's first two siRNA candidates using Tekmira's Stable Nucleic Acid-Lipid Particle (SNALP) delivery system.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies